Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

Blood (2024) 144 (18): 1924–1935.

https://doi.org/10.1182/blood.2024024631

Published: 2024

Includes: Supplemental data

Journal Articles

The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia

Blood (2023) 142 (Supplement 1): 4639.

https://doi.org/10.1182/blood-2023-188827

Published: 2023

Journal Articles

Clinical Outcomes of Chronic Myeloid Leukaemia (CML) Patients on Asciminib through the Managed Access Program (MAP) in Australia

Lynette C.Y. Chee, Nora Lee, Andrew Grigg, Melissa Chen, Anthony Schwarer, Jeff Szer, David T Yeung, Timothy Hughes, Naranie Shanmuganathan

Blood (2022) 140 (Supplement 1): 6800–6802.

https://doi.org/10.1182/blood-2022-163221

Published: 2022

Journal Articles

Duration of ≥MR4 Is the Best Predictor for a Successful 1 st Treatment-Free Remission (TRF1) Attempt in CML Patients Treated with Tyrosine Kinase Inhibitors (TKI); Long-Term Follow-up of a Large Cohort of Patients Including a Cohort Undergoing a 2 nd Tfr (TFR2) Attempt

James Anthony Schwarer, Anthony Schwarer

Blood (2022) 140 (Supplement 1): 3900–3901.

https://doi.org/10.1182/blood-2022-168855

Published: 2022

Journal Articles

The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3 -ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3 -ITD Acute Myeloid Leukemia (ALLG AMLM16)

Natasha S Anstee, PhD, Giovanna Pomilio, Mark Levis, MD PhD, Sarah MacRaild, Michael Murray, PhD DSc, Tristan Rawling, PhD, Glen A Kennedy, MBBS FRACP FRCPA, Andrew Grigg, MBBS, MD FRACP, FRCPA, Anthony Schwarer, MBBS, MD FRACP, FRCPA, Anoop Kumar Enjeti, MBBS,FRCPA, FRACP, PhD MD MRCP, James D'Rozario, MBBS, FRACP, FRCPA, Paula Marlton, MBBS FRACP FRCPA, Ian Bilmon, BMBS, FRACP, FRCPA, Adam Ivey, BSc, MSc, PhD, Doen Ming Ong, MBBS, Andrew W Roberts, MBBS, Andrew H Wei, MBBS, PhD

Blood (2020) 136 (Supplement 1): 16–18.

https://doi.org/10.1182/blood-2020-141711

Published: 2020

Journal Articles

Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)

Blood (2020) 136 (Supplement 1): 36–38.

https://doi.org/10.1182/blood-2020-137334

Published: 2020

Journal Articles

Leopard: A Phase II Study of Maintenance Lenalidomide and Prednisolone Post Autologous Stem Cell Transplantation (ASCT) for Myeloma, Incorporating Minimal Residual Disease Assessments

Anna Kalff, MBBS, FRACP, FRCPA, Nola Kennedy, Patricia A. Walker, MBBS, FRACP, FRCPA, Tiffany T. Khong, BSc, PhD, Anthony Schwarer, MD, Andrew W. Roberts, MBBS, PhD, Philip Campbell, MBBS, FRACP, FRCPA, Robin Filshie, PhD FRACP, Angela Smiley, Malgorzata Gorniak, Marion Black, Nicole Jenkins, Geoffrey Raines, Andrew Spencer, MBBS FRACP FRCPA MD

Blood (2014) 124 (21): 2103.

https://doi.org/10.1182/blood.V124.21.2103.2103

Published: 2014

Journal Articles

Maintaining Imatinib ≥600 Mg Daily in the First 12 Months of Chronic Phase CML Treatment Is Associated with Superior Event-Free Survival at 5 Years.

Blood (2009) 114 (22): 1125.

https://doi.org/10.1182/blood.V114.22.1125.1125

Published: 2009

Journal Articles

Early Dose-Escalation in Chronic Myeloid Leukaemia Patients with Low Plasma Imatinib Levels Leads to Equivalent BCR-ABL Values and Drug Levels at 6 Months to Those with Optimal Drug Levels: First Analysis From the TIDEL II Trial of De-Novo Patients Treated with 600mg Imatinib.

Michael P Osborn, Deborah L White, PhD, Verity A Saunders, Bronwyn Cambareri, Susan Branford, PhD, Andrew Menelaou, Bereha Khodr, PhD, Cassandra Slader, Mark Hertzberg, Anthony Schwarer, David Ma, MD, Christopher Arthur, Cecily J. Forsyth, Samar Issa, Yiu Lam Kwan, John Taper, Andrew Grigg, Timothy P. Hughes, MD

Blood (2009) 114 (22): 1131.

https://doi.org/10.1182/blood.V114.22.1131.1131

Published: 2009

Journal Articles

The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a Sustained Complete Molecular Response (CMR) Remain in CMR, and Any Relapses Occur Early.

Davi D M Ross, Andrew Grigg, Anthony Schwarer, Christopher Arthur, Kerryn Loftus, Anthony K Mills, Robin Filshie, Ruth Columbus, John Reynolds, John F Seymour, MB, BS, PhD, FRACP, Susan Branford, Timothy Hughes

Blood (2008) 112 (11): 1102.

https://doi.org/10.1182/blood.V112.11.1102.1102

Published: 2008

Journal Articles

Long Term Follow up of Patients with CML in Chronic Phase Treated with First-Line Imatinib Suggests That Earlier Achievement of a Major Molecular Response Leads to Greater Stability of Response.

Susan Branford, Rebecca Lawrence, Andrew Grigg, John Francis Seymour, MBBS, Anthony Schwarer, Christopher Arthur, Zbigniew Rudzki, Timothy Hughes

Blood (2008) 112 (11): 2113.

https://doi.org/10.1182/blood.V112.11.2113.2113

Published: 2008

Journal Articles

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

Blood (2008) 112 (10): 3965–3973.

https://doi.org/10.1182/blood-2008-06-161737

Published: 2008

Includes: Supplemental data

Journal Articles

The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia

Alberto Catalano, Mark A. Dawson, Karthiga Somana, Stephen Opat, Anthony Schwarer, Lynda J. Campbell, Harry Iland

Blood (2007) 110 (12): 4073–4076.

https://doi.org/10.1182/blood-2007-06-095554

Published: 2007

Includes: Supplemental data

Journal Articles

Maintenance of Imatinib Dose Intensity in the First Six Months of Therapy for Newly Diagnosed Patients with CML Is Predictive of Molecular Response, Independent of the Ability To Increase Dose at a Later Point.

Timothy P. Hughes, Susan Branford, John Reynolds, Rachel Koelmeyer, John Seymour, Kerry Taylor, Nancy Guzzo-Pernell, Robin Filshie, Chris Arthur, Anthony Schwarer, Mark Hertzberg, Michael Copeman, Kevin Lynch, Andrew Grigg

Blood (2005) 106 (11): 164.

https://doi.org/10.1182/blood.V106.11.164.164

Published: 2005

NARROW

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia

Clinical Outcomes of Chronic Myeloid Leukaemia (CML) Patients on Asciminib through the Managed Access Program (MAP) in Australia

Duration of ≥MR4 Is the Best Predictor for a Successful 1 st Treatment-Free Remission (TRF1) Attempt in CML Patients Treated with Tyrosine Kinase Inhibitors (TKI); Long-Term Follow-up of a Large Cohort of Patients Including a Cohort Undergoing a 2 nd Tfr (TFR2) Attempt

The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3 -ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3 -ITD Acute Myeloid Leukemia (ALLG AMLM16)

Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)

Leopard: A Phase II Study of Maintenance Lenalidomide and Prednisolone Post Autologous Stem Cell Transplantation (ASCT) for Myeloma, Incorporating Minimal Residual Disease Assessments

Maintaining Imatinib ≥600 Mg Daily in the First 12 Months of Chronic Phase CML Treatment Is Associated with Superior Event-Free Survival at 5 Years.

Early Dose-Escalation in Chronic Myeloid Leukaemia Patients with Low Plasma Imatinib Levels Leads to Equivalent BCR-ABL Values and Drug Levels at 6 Months to Those with Optimal Drug Levels: First Analysis From the TIDEL II Trial of De-Novo Patients Treated with 600mg Imatinib.

The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a Sustained Complete Molecular Response (CMR) Remain in CMR, and Any Relapses Occur Early.

Long Term Follow up of Patients with CML in Chronic Phase Treated with First-Line Imatinib Suggests That Earlier Achievement of a Major Molecular Response Leads to Greater Stability of Response.

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia

Maintenance of Imatinib Dose Intensity in the First Six Months of Therapy for Newly Diagnosed Patients with CML Is Predictive of Molecular Response, Independent of the Ability To Increase Dose at a Later Point.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only